Inside the research
Pfizer Inc.
PFE Research profile · latest available data
Price overview
$28.67
▲ +0.26 (+0.9%)
| 52w hi | $29.02 |
|---|---|
| 52w lo | $22.05 |
| Vol | 27.76M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.31
| Short | +0.26 |
|---|---|
| Medium | +0.42 |
| Long | +0.22 |
computed 2026-09-27
Key fundamentals
Pfizer Inc.
Healthcare · Drug Manufacturers - General
| Market cap | $163.41B |
|---|---|
| Enterprise value | $215.49B |
| Trailing P/E | 37.72x |
| Forward P/E | 9.90x |
| EV / EBITDA | 8.49x |
| P / S (ttm) | 2.57x |
| Profit margin | 6.8% |
| Return on equity | 5.0% |
| Revenue growth | +2.6% |
| Debt / equity | 74.25 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.19 | |
| Sector | +0.08 | |
| Technical | +0.21 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Risk Metrics
| Beta vs SPX | 0.40 |
|---|---|
| Corr SPX | 0.27 |
| Annual vol | 24.3% |
| Annual ret | +1.7% |
| Sharpe | 0.07 |
| Max DD | -28.5% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $29.11 |
|---|---|
| High / Low | $36.00 / $24.00 |
| Median | $28.00 |
| Analysts | 27 |
| Strong Buy | 2 | |
|---|---|---|
| Buy | 9 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 2 |
Recent rating actions
| 2026-04-29 | Citigroup | → Neutral |
| 2026-04-20 | RBC Capital | → Underperform |
| 2026-04-16 | CICC | → Outperform |
| 2026-04-13 | UBS | → Neutral |
| 2026-04-10 | Morgan Stanley | → Equal-Weight |
| 2026-04-09 | B of A Securities | → Neutral |
Officers & Board
| Director | James Quincey since 2020 |
|---|---|
| Director | Susan Desmond-Hellmann since 2020 |
| Director | Susan Hockfield since 2020 |
| Director | Scott Gottlieb since 2019 |
| CEO | Albert Bourla since 2019 |
| Director | Albert Bourla since 2018 |
| Director | Dan Littman since 2018 |
| Director | Ronald E. Blaylock since 2017 |
| Director | Joe Echevarria since 2015 |
| Director | James C. Smith since 2014 |
| Director | Shantanu Narayen since 2013 |
| Director | Helen Hobbs since 2011 |
| Director | Suzanne Nora Johnson since 2007 |
| Founder | Charles Pfizer current |
| Founder | Charles F. Erhart current |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-04 | Earnings Release, Exhibits | read |
| 2026-06-18 | Officer / Director Change, Exhibits | read |
| 2026-06-18 | Reg FD Disclosure | read |
| 2026-05-05 | Earnings Release, Exhibits | read |
| 2026-04-27 | Shareholder Vote | read |
| 2026-02-03 | Earnings Release, Exhibits | read |
| 2025-12-16 | Reg FD Disclosure, Exhibits | read |
| 2025-11-21 | Other Material Event, Exhibits | read |
| 2025-11-13 | Other Material Event | read |
| 2025-11-04 | Earnings Release, Exhibits | read |
| 2025-08-05 | Earnings Release, Exhibits | read |
| 2025-05-19 | Other Material Event, Exhibits | read |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 8 |
| Top-5 share | 98.3% |
| HHI | 5,978 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $7.39B | 307.09M |
| Citadel Advisors | $787.65M | 32.71M |
| Capital Research / Capital World | $505.45M | 20.99M |
| AQR Capital Management | $445.02M | 18.56M |
| Fidelity / FMR LLC | $370.77M | 15.40M |
| Millennium Management | $162.75M | 6.76M |
| Bridgewater Associates | $4.34M | 180.09K |
| T. Rowe Price Group | $349.57K | 14.52M |
As of 2026-06-30
Dividends
| Yield (TTM) | 4.50% |
|---|---|
| $ / share (TTM) | $1.29 |
| 5y CAGR | +3.6% |
Annual dividend per share
| 2021 | $1.56 |
|---|---|
| 2022 | $1.60 |
| 2023 | $1.64 |
| 2024 | $1.68 |
| 2025 | $1.72 |
| 2026 | $0.86 |
SEC Filings
The Long Run
FY 2009–2025 · 17 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $62.58B | +1.6% | |
| Net income | $2.12B | -8.1% | |
| Cash from ops | $11.70B | -2.2% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $28.45 | $28.69 | $28.17 | $28.67 | 27.76M |
| Sep 24 | $28.20 | $28.85 | $28.20 | $28.41 | 34.77M |
| Sep 23 | $27.96 | $28.23 | $27.84 | $28.18 | 33.81M |
| Sep 22 | $27.74 | $28.00 | $27.49 | $27.93 | 26.66M |
| Sep 21 | $27.65 | $27.92 | $27.53 | $27.74 | 28.77M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →